中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
22期
18-19
,共2页
依达拉奉%急性心肌梗死%肌钙蛋白Ⅰ%C-反应蛋白%再灌注损伤
依達拉奉%急性心肌梗死%肌鈣蛋白Ⅰ%C-反應蛋白%再灌註損傷
의체랍봉%급성심기경사%기개단백Ⅰ%C-반응단백%재관주손상
Edaravolle%Acute myocardial infarction%Troponin Ⅰ%C-reactive protein%Reperfusion injury
目的 探讨依达拉奉对急性心肌梗死(AMI)溶栓后肌钙蛋白Ⅰ和C-反应蛋白的影响.方法 将60例AMI患者随机分为治疗组30例与对照组30例.观察两组再灌注后心律失常发生率,测定溶栓后2、24h的磷酸肌酸激酶同工酶(CK-MB)和心肌肌钙蛋白Ⅰ(cTrI),溶栓后24 h、48 h、7d的C-反应蛋白.结果 两组治疗后24h的CK-MB和2、24h的cTnI及治疗后48 h、7d的C-反应蛋白比较差异有统计学意义(P＜0.05).结论 急性心肌梗死时在常规治疗基础上加用依达拉奉,可明显减轻再灌注损伤,改善AMI患者的生存率及预后.
目的 探討依達拉奉對急性心肌梗死(AMI)溶栓後肌鈣蛋白Ⅰ和C-反應蛋白的影響.方法 將60例AMI患者隨機分為治療組30例與對照組30例.觀察兩組再灌註後心律失常髮生率,測定溶栓後2、24h的燐痠肌痠激酶同工酶(CK-MB)和心肌肌鈣蛋白Ⅰ(cTrI),溶栓後24 h、48 h、7d的C-反應蛋白.結果 兩組治療後24h的CK-MB和2、24h的cTnI及治療後48 h、7d的C-反應蛋白比較差異有統計學意義(P＜0.05).結論 急性心肌梗死時在常規治療基礎上加用依達拉奉,可明顯減輕再灌註損傷,改善AMI患者的生存率及預後.
목적 탐토의체랍봉대급성심기경사(AMI)용전후기개단백Ⅰ화C-반응단백적영향.방법 장60례AMI환자수궤분위치료조30례여대조조30례.관찰량조재관주후심률실상발생솔,측정용전후2、24h적린산기산격매동공매(CK-MB)화심기기개단백Ⅰ(cTrI),용전후24 h、48 h、7d적C-반응단백.결과 량조치료후24h적CK-MB화2、24h적cTnI급치료후48 h、7d적C-반응단백비교차이유통계학의의(P＜0.05).결론 급성심기경사시재상규치료기출상가용의체랍봉,가명현감경재관주손상,개선AMI환자적생존솔급예후.
Objective To investigate the effect of edaravone on troponin Ⅰ and C-reactive protein in acute myocardial infarction(AMI) after thrombolysis.Methods Sixty cases of AMI patients were randomly divided into treatment group(n =30) and control group(n =30).The incidence of reperfusion arrhythmias was observed,and the levels of CK-MB and cardiac troponin Ⅰ(cTnI) at 2 hours,24 havs,and the levels of C-reactive protein at 24 h,48 h,7 d were measured.Results After treatment,there were significantly differences in 24 hour of CK-MB,2 hours and 24 hours of cTnI and 48 hour,7 days of C-reactive protein levels between the two groups(P ＜0.05).Conclusions Application of edaravone on the basis of conventional therapy,can significantly reduce reperfusion injury in acute myocardial infarction,improve the survival rote and prognosis of patients with AMI.
